Thelansis

Keratoconus Market Outlook Thelansis’s “Keratoconus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Keratoconus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed...

  Keratoconus Market Outlook Thelansis’s “Keratoconus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Keratoconus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Keratoconus Overview Keratoconus is a bilateral and asymmetric cornea disease characterized by progressive thinning, steepening, irregular astigmatism, and decreased visual acuity. Environmental and familial factors are associated with an increased risk of developing the condition. Eye rubbing is also a strong risk factor in the pathogenesis of keratoconus. Classification systems based on morphological changes and disease evolution are Morphological (Buxton), Keratomet...

  Glaukos Corporation announced that the second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on) met its pre-specified primary efficacy endpoint. This next-generation corneal cross-linking iLink therapy demonstrated a statistically significant and clinically relevant improvement in maximum corneal curvature (Kmax) at 12 months from baseline compared to the sham/placebo-controlled arm. Kmax is an FDA-accepted primary efficacy outcome for keratoconus pivotal trials, measuring the steepest corneal curvature and indicating disease progression. Publish Date: 16-10-2024   Source: Glaukos Corporation Keratoconus is a bilateral and asymmetric cornea disease characterized by progressive thinning, steepening, irregular astigmatism, and decreased visual acuity. Environmental and familial factors are associated with an increased risk of developing the condition. Eye rubbing is also a strong risk factor in the pathogenesis of keratoconus. Classification systems based on mor...

  Keratoconus is a bilateral and asymmetric cornea disease characterized by progressive thinning, steepening, irregular astigmatism, and decreased visual acuity. Environmental and familial factors are associated with an increased risk of developing the condition. Eye rubbing is also a strong risk factor in the pathogenesis of keratoconus. Classification systems based on morphological changes and disease evolution are Morphological (Buxton), Keratometric, Hom's, and Amsler-Krumeich. The condition typically develops in the second and third decades of life and progresses until the fourth decade, when it stabilizes. It can also develop earlier or later in life. The condition typically affects both eyes, although with different degrees of severity. While there is no clear consensus on the signs and symptoms associated with early keratoconus, subclinical or form-fruste keratocon us is commonly used to describe the early stages of the disease. Worldwide occurrence of keratoconus, with...